Study wrapper · #1199
Burden and Risk of Depression in Patients Receiving Semaglutide: A Systematic Review and Meta-Analysis.
Editor's note
This is the broadest pooled look yet at the semaglutide mental-health question, and its answer lines up with earlier regulatory reviews by the FDA and EMA: no statistically significant psychiatric signal. The point estimates do lean above 1.0, and heterogeneity is extreme (I-squared above 90 percent), so the confidence intervals are wide and the certainty of evidence is low. The authors' own framing — reassuring but not conclusive — is the right one, and we should mirror that restraint. A useful data point for readers weighing the persistent anecdotal reports against the aggregate evidence.
Plain-language abstract
There has been ongoing debate about whether semaglutide affects mood, including worries about depression and suicidal thoughts. This meta-analysis pooled trials, observational studies, and safety-report databases through January 2026 to check for a signal. Across all three outcomes — depression, anxiety, and suicidal ideation — people receiving semaglutide showed no statistically significant increase compared with people who did not receive it. The authors caution that the underlying studies varied a lot in quality, so this is best read as no detected risk so far rather than definitive proof of safety.